☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics' Losmapimod Receives the US FDA's Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy
May 13, 2021
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy
September 17, 2019
Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscap...
April 24, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
